

**HCMV-encoded miR-UL112-3p promotes glioblastoma progression via tumour suppressor**

**candidate 3**

Qing Liang<sup>1</sup>, Kejia Wang<sup>2</sup>, Qiliang Cai<sup>1, \*</sup>, Bin Wang<sup>2, \*</sup>


<sup>1</sup> MOE&MOH Key Laboratory of Medical Molecular Virology, School of Basic Medical Sciences,

Shanghai Medical College, Fudan University, Shanghai 200032, China

<sup>2</sup> Department of Special Medicine, Qingdao University, Qingdao 266071, Shandong, China


\* Correspondence to: Qi-Liang Cai, E-mail: qiliang@fudan.edu.cn

Bin Wang, E-mail: qdwangbin1962@163.com



**Figure S1.** IE86 expression was verified by immunohistochemistry in HCMV-positive GBM

specimens.




**Figure S2.** miR-UL112-3p regulates primary GBM cell growth in vitro. Primary GBM cells were

transfected with the miR-UL112-3p mimics/inhibitor for 48 h. (A). The expression of miR-UL112-3p


was measured by qPCR analysis. (B). The CCK-8 assay was performed to examine cell proliferation at

the indicated time points. (C-E). Cell viability of GBM cells upon TMZ and radiation treatments. Data


are expressed as the mean  $\pm$  SD. \*,  $P < 0.05$ ,  $n = 5$ .











**Figure S3.** miR-UL112-3p modulates the clone-formation, invasion and migration in primary GBM cells. **(A).** The representative images of the clone-formation assay. **(B).** Quantification of the colony number of GBM cells after 14 days of incubation. **(C).** The representative images of invasive GBM cells after 24 h of culture in Matrigel invasion chambers. **(D).** Quantification of the number of transmembrane cells. **(E).** Representative images were taken at 0 and 24 h to assess the cell migration into the open space. **(F).** Quantification of the migration distance was achieved by measuring wound closure. The data are expressed as the mean  $\pm$ SD. \*,  $P < 0.05$ ,  $n = 5$ .




**Figure S4.** The Full-length immunblots as shown in Figure 5E.




**Figure S5.** The Full-length immunblots as shown in Figure 5F.









**Figure S6.** The Full-length immunoblots as shown in Figure 5F.



**Figure S7.** The Full-length immunoblots as shown in Figure 6A.



**Figure S8.** The Full-length immunoblots as shown in Figure 7A.